Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020

BRIDGEWATER, N.J., April 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2020 financial results on Thursday, April 30, 2020.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, April 30, 2020 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing [phone] (domestic) or [phone] (international) and referencing conference ID number 2121512. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately one hour after its completion through May 14, 2020 by dialing [phone] (domestic) or [phone] (international) and referencing replay access code 10142785. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE^® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.

Contact:

Investors:

Argot Partners
Laura Perry or Heather Savelle
[phone]
[e-mail]

Media:

Mandy Fahey
Senior Director, Corporate Communications
Insmed
[phone]
[e-mail]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-first-quarter-2020-financial-results-conference-call-on-thursday-april-30-2020-301042223.html

SOURCE Insmed Incorporated

Copyright 2020 PR Newswire